Program Description: For most patients with advanced hematologic malignancies treatment options remain limited. However, with the rapid development of the high throughput analytical methods and our advancing understanding of the molecular pathogenesis of blood cancers, new therapies become available. This symposium will provide an overview of newest therapeutic strategies for hematologic malignancies. It will bring together basic and clinical scientists to outline current treatment options and discuss potential future targets.
Target Audience: Hematologists/Oncologists, Hematology/Oncology fellows, Hemato-pathologists, Physician Assistants, Nurse Practitioners, Pharmacists, Internal Medicine Residents, Basic Research Scientists.
At the conclusion of this activity, participants should be able to:
Recognize dysregulated signaling pathways in hematologic malignancies and indicate current and potential therapeutic targets.
Identify immunologic barriers created by hematologic malignancies and cite methods by which they can be overcome.
Distinguish disease and class specific treatments for hematologic malignancies.
Learn More | Register Online
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Warren Alpert Medical School of Brown University and Division of Hematology/Oncology at Rhode Island Hospital and The Miriam Hospital. The Warren Alpert Medical School of Brown University is accredited by the ACCME to provide continuing medical education for physicians.
Physicians: The Warren Alpert Medical School of Brown University designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their...